Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience.

Journal: Clinical kidney journal
Published Date: Oct 11, 2017

Abstract

BACKGROUND: Persistent significant proteinuria has been associated with increased risk of progression to end-stage kidney disease in patients with idiopathic membranous nephropathy (IMN). Rituximab (RTX) therapy has given encouraging results in IMN, but most of the studies have used a higher dose, which is limited by the high cost as well as a potential increased risk of infections. Our study aimed to assess the efficacy and safety of low-dose RTX in patients with immunosuppression-resistant IMN.

Authors

  • Soumita Bagchi
    Department of Nephrology, AIIMS, New Delhi, India.
  • Arun Kumar Subbiah
    Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India.
  • Dipankar Bhowmik
    Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India.
  • Sandeep Mahajan
    Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India.
  • Raj Kanwar Yadav
    Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India.
  • Mani Kalaivani
    Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
  • Geetika Singh
    Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
  • Amit Dinda
    Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
  • Sanjay Kumar Agarwal
    Department of Nephrology, All India Institute of Medical Sciences, New Delhi, India.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals